دورية أكاديمية
Factor XI/XIa inhibitors for the prevention and treatment of venous and arterial thromboembolism: A narrative review.
| العنوان: | Factor XI/XIa inhibitors for the prevention and treatment of venous and arterial thromboembolism: A narrative review. |
|---|---|
| المؤلفون: | Prakash S; Department of Internal Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA., Mares AC; Department of Internal Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA.; Yale University School of Medicine, New Haven, CT, USA., Porres-Aguilar M; Department of Internal Medicine, Divisions of Hospital and Adult Thrombosis Medicine, Texas Tech University Health Sciences Center and Paul L Foster School of Medicine, El Paso, TX, USA., Mukherjee D; Division of Cardiovascular Diseases, Texas Tech University Health Sciences Center and Paul L Foster School of Medicine, El Paso, TX, USA., Barnes GD; Department of Internal Medicine, Division of Cardiovascular Medicine, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI, USA. |
| المصدر: | Vascular medicine (London, England) [Vasc Med] 2024 Feb; Vol. 29 (1), pp. 85-92. Date of Electronic Publication: 2023 Nov 10. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: SAGE Publications Country of Publication: England NLM ID: 9610930 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-0377 (Electronic) Linking ISSN: 1358863X NLM ISO Abbreviation: Vasc Med Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: London : SAGE Publications Original Publication: London, UK : Letchworth, Hertfordshire, UK : Arnold ; Turpin Distribution Services, c1996- |
| مواضيع طبية MeSH: | Venous Thrombosis*/diagnosis , Venous Thrombosis*/drug therapy , Venous Thrombosis*/prevention & control , Venous Thromboembolism*/diagnosis , Venous Thromboembolism*/drug therapy , Venous Thromboembolism*/prevention & control, Humans ; Anticoagulants/adverse effects ; Factor XI/therapeutic use ; Hemorrhage/chemically induced ; Hemorrhage/drug therapy |
| مستخلص: | During the past decade, direct oral anticoagulants (DOACs) have advanced and simplified the prevention and treatment of venous thromboembolism (VTE). However, there remains a high incidence of bleeds, which calls for agents that have a reduced risk of bleeding. Factor XI (FXI) deficiency is associated with lower rates of venous thrombosis and stroke compared to the general population with a lower risk of bleeding. In conjunction with this, phase 2 studies have demonstrated safety and the potential for reduced thrombotic events with FXI inhibitors as compared to currently available medications. The aim of this review is to summarize key data on the clinical pharmacology of FXI, the latest developments in clinical trials of FXI inhibitors, and to describe the efficacy and safety profiles of FXI inhibitors for the prevention of venous and arterial thromboembolism. Competing Interests: Declaration of conflicting interestsDr. Barnes serves on the Board of Directors for the Anticoagulation Forum and as a consultant for Pfizer, Bristol-Myers Squibb, Janssen, Bayer, AstraZeneca, Sanofi, Anthos, Abbott Vascular, and Boston Scientific. The other authors have no conflicts of interest. |
| فهرسة مساهمة: | Keywords: anticoagulation; bleeding events; factor XI; thromboprophylaxis; thrombosis; venous thromboembolism (VTE) |
| المشرفين على المادة: | 0 (Anticoagulants) 9013-55-2 (Factor XI) |
| تواريخ الأحداث: | Date Created: 20231110 Date Completed: 20240214 Latest Revision: 20240429 |
| رمز التحديث: | 20240429 |
| DOI: | 10.1177/1358863X231206778 |
| PMID: | 37947131 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1477-0377 |
|---|---|
| DOI: | 10.1177/1358863X231206778 |